Scarica l'app Stockscreener
0.8445
2.98%
0.0244
Precedente Chiudi:
$0.8201
Aprire:
$0.83
Volume 24 ore:
1,847
Relative Volume:
0.01
Capitalizzazione di mercato:
$30.54M
Reddito:
-
Utile/perdita netta:
$-8.53M
Rapporto P/E:
-3.4696
EPS:
-0.2434
Flusso di cassa netto:
$-12.75M
1 W Prestazione:
-4.02%
1M Prestazione:
-9.33%
6M Prestazione:
-28.43%
1 anno Prestazione:
-36.50%
Intervallo 1D:
$0.83
$0.8599
Intervallo di 1 settimana:
$0.78
$0.8919
Portata 52W:
$0.63
$3.23
Estrella Immunopharma Inc Stock (ESLA) Company Profile
Nome
Estrella Immunopharma Inc
Settore
Industria
Telefono
(510) 318-9098
Indirizzo
5858 HORTON STREET, SUITE 370, EMERYVILLE
Confronta ESLA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ESLA
Estrella Immunopharma Inc
|
0.8445 | 33.41M | 0 | -8.53M | -12.75M | -0.2434 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.83 | 123.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
544.39 | 60.43B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.06 | 42.07B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
570.38 | 34.47B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
296.84 | 27.42B | 3.81B | -644.79M | -669.77M | -6.24 |
Estrella Immunopharma Inc Borsa (ESLA) Ultime notizie
Is Estrella Immunopharma Inc. stock overhyped or has real potentialSolid Return Trade Selections - Newser
What makes Estrella Immunopharma Inc. stock price move sharplyTop Growth Low Risk Stocks - Newser
Why Estrella Immunopharma Inc. stock attracts strong analyst attentionLong Term Low Risk Growth - Newser
How Estrella Immunopharma Inc. stock performs during market volatilitySmall Risk Large Return Trades - Newser
Estrella Immunopharma Expands STARLIGHT-1 Trial with New Texas Clinical Site - MSN
Estrella Immunopharma opens new trial site for cancer therapy By Investing.com - Investing.com South Africa
Estrella Immunopharma Announces Activation of Additional Site for Phase I/II Starlight-1 Trial in B-Cell Non-Hodgkin's Lymphoma - MarketScreener
Estrella Immunopharma Announces Activation of Additional Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma - BioSpace
Estrella Immunopharma (ESLA) Expands Clinical Trial with New Sit - GuruFocus
Estrella Immunopharma opens new trial site for cancer therapy - Investing.com Australia
Estrella Immunopharma Expands STARLIGHT-1 Clinical Trial - TipRanks
Estrella Immunopharma Announces Activation Of Additional Site For Phase I/Ii Starlight-1 Trial In B-Cell Non-Hodgkin'S Lymphoma - marketscreener.com
Estrella Immunopharma secures $3.35M in financing to advance clinical triall; shares up - MSN
Analyst Maintains Buy Rating on Estrella Immunopharma (ESLA) | E - GuruFocus
Estrella Immunopharma secures $3.35 million in PIPE financing By Investing.com - Investing.com South Africa
Analyst Maintains Buy Rating on Estrella Immunopharma (ESLA) | ESLA Stock News - GuruFocus
Estrella Immunopharma (ESLA) Secures $3.35M Through Private Equi - GuruFocus
Estrella Immunopharma secures $3.35 million in PIPE financing - Investing.com Australia
Estrella Immunopharma Announces Approximately $3.35 Million Private Placement Equity Financing - Business Wire
ESLA’s Latest Gains: What’s Behind the Surge? - StocksToTrade
Estrella Immunopharma’s (ESLA) “Buy” Rating Reaffirmed at D. Boral Capital - Defense World
Estrella Immunopharma, Inc. (ESLA) Doses First Patient in Higher-Dose Cohort of EB103 Phase I/II Trial - Yahoo
ESLA Stock Rating and Price Target Maintained by D. Boral Capita - GuruFocus
Estrella Immunopharma, Inc. Initiates Second Cohort and Doses First Patient in STARLIGHT-1 Trial of EB103 in Advanced B-Cell Non-Hodgkin's Lymphomas - marketscreener.com
Estrella Immunopharma Advances STARLIGHT-1 Clinical Trial - TipRanks
Estrella Immunopharma Initiates Second Cohort and Doses First Patient in STARLIGHT-1 Trial of EB103 in Advanced B-Cell Non-Hodgkin’s Lymphomas - BioSpace
ESLA Stock Rating and Price Target Maintained by D. Boral Capital | ESLA Stock News - GuruFocus
Estrella Immunopharma Initiates Second Cohort and Doses First Patient in STARLIGHT-1 Trial of EB103 in Advanced B-Cell Non-Hodgkin's Lymphomas - marketscreener.com
Estrella Immunopharma (ESLA) Advances in Phase I/II STARLIGHT-1 Trial | ESLA Stock News - GuruFocus
Geode Capital Management LLC Acquires 16,862 Shares of Estrella Immunopharma, Inc. (NASDAQ:ESLA) - Defense World
ESLA Stock: A Voyage Through Estrella Immunopharma Inc’s Finances - investchronicle.com
A stock that deserves closer examination: Estrella Immunopharma Inc (ESLA) - uspostnews.com
Estrella Immunopharma Achieves Complete Response in First Patient Treated with CD19- Redirected ARTEMIS - Business Wire
Estrella Immunopharma, Inc. (NASDAQ: ESLA) Receives Buy Rating With a Price Target of $14.00 From CB Capital Partners - BioSpace
Estrella Immunopharma completes first dose cohort in STARLIGHT trial - Yahoo Finance
Sector Update: Health Care -February 21, 2025 at 03:42 pm EST - Marketscreener.com
Estrella Immunopharma Completes First Dose Group in Non-Hodgkin Lymphoma Study - Marketscreener.com
Estrella Immunopharma Inc Azioni (ESLA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.86%
0.10%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):